Logo image of NAVB

NAVIDEA BIOPHARMACEUTICALS I (NAVB) Stock Fundamental Analysis

USA - NYSEARCA:NAVB - US63937X2027 - Common Stock

0.0779 USD
0 (-2.99%)
Last: 10/5/2023, 8:04:00 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to NAVB. NAVB was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of NAVB have multiple concerns. NAVB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NAVB had negative earnings in the past year.
In the past year NAVB has reported a negative cash flow from operations.
NAVB had negative earnings in each of the past 5 years.
In the past 5 years NAVB reported 4 times negative operating cash flow.
NAVB Yearly Net Income VS EBIT VS OCF VS FCFNAVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M 60M

1.2 Ratios

NAVB has a Return On Assets of -209.43%. This is amonst the worse of the industry: NAVB underperforms 93.23% of its industry peers.
Industry RankSector Rank
ROA -209.43%
ROE N/A
ROIC N/A
ROA(3y)-239.03%
ROA(5y)-242.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NAVB Yearly ROA, ROE, ROICNAVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 2K 4K 6K 8K 10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NAVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NAVB Yearly Profit, Operating, Gross MarginsNAVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -10K -20K

More info and screens

0

2. Health

2.1 Basic Checks

NAVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NAVB has more shares outstanding
NAVB has a worse debt/assets ratio than last year.
NAVB Yearly Shares OutstandingNAVB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
NAVB Yearly Total Debt VS Total AssetsNAVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

NAVB has an Altman-Z score of -70.66. This is a bad value and indicates that NAVB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -70.66, NAVB is not doing good in the industry: 98.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -70.66
ROIC/WACCN/A
WACC9.82%
NAVB Yearly LT Debt VS Equity VS FCFNAVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 0.84 indicates that NAVB may have some problems paying its short term obligations.
NAVB has a worse Current ratio (0.84) than 92.90% of its industry peers.
NAVB has a Quick Ratio of 0.84. This is a bad value and indicates that NAVB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NAVB (0.79) is worse than 93.56% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.79
NAVB Yearly Current Assets VS Current LiabilitesNAVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

NAVB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.35%.
The Revenue for NAVB has decreased by -87.65% in the past year. This is quite bad
The Revenue for NAVB have been decreasing by -48.49% on average. This is quite bad
EPS 1Y (TTM)-39.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%221.1%
Revenue 1Y (TTM)-87.65%
Revenue growth 3Y-53.62%
Revenue growth 5Y-48.49%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NAVB Yearly Revenue VS EstimatesNAVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
NAVB Yearly EPS VS EstimatesNAVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2019 2020 2021 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NAVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NAVB Price Earnings VS Forward Price EarningsNAVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NAVB Per share dataNAVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NAVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NAVIDEA BIOPHARMACEUTICALS I

NYSEARCA:NAVB (10/5/2023, 8:04:00 PM)

0.0779

0 (-2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2023-08-11/amc
Earnings (Next)11-13 2023-11-13/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners11.76%
Ins Owner Change0%
Market Cap7.80M
Revenue(TTM)65.65K
Net Income(TTM)-17.22M
Analysts82.86
Price Target5.1 (6446.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 118.75
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -209.43%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-239.03%
ROA(5y)-242.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 241.56%
Cap/Sales 389.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.79
Altman-Z -70.66
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)474.48%
Cap/Depr(5y)298.68%
Cap/Sales(3y)233.93%
Cap/Sales(5y)142.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%221.1%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-87.65%
Revenue growth 3Y-53.62%
Revenue growth 5Y-48.49%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y87.6%
OCF growth 3YN/A
OCF growth 5YN/A

NAVIDEA BIOPHARMACEUTICALS I / NAVB FAQ

What is the fundamental rating for NAVB stock?

ChartMill assigns a fundamental rating of 0 / 10 to NAVB.


Can you provide the valuation status for NAVIDEA BIOPHARMACEUTICALS I?

ChartMill assigns a valuation rating of 0 / 10 to NAVIDEA BIOPHARMACEUTICALS I (NAVB). This can be considered as Overvalued.


Can you provide the profitability details for NAVIDEA BIOPHARMACEUTICALS I?

NAVIDEA BIOPHARMACEUTICALS I (NAVB) has a profitability rating of 0 / 10.


How financially healthy is NAVIDEA BIOPHARMACEUTICALS I?

The financial health rating of NAVIDEA BIOPHARMACEUTICALS I (NAVB) is 0 / 10.


Is the dividend of NAVIDEA BIOPHARMACEUTICALS I sustainable?

The dividend rating of NAVIDEA BIOPHARMACEUTICALS I (NAVB) is 0 / 10 and the dividend payout ratio is 0%.